09:24 AM EDT, 08/19/2024 (MT Newswires) -- CollPlant Biotechnologies ( CLGN ) and Stratasys ( SSYS ) said Monday they have begun a pre-clinical study aimed at assessing the ability of 3D-printed regenerative breast implants to grow natural tissue while fully degrading over time.

The implants, made with CollPlant's collagen-based bioinks and printed on Stratasys' ( SSYS ) Origin system, are designed as a potential alternative to silicone implants for reconstructive and cosmetic use, the companies said.

Initial results are expected in the first half of 2025, they added.

Shares of CollPlant were up 2.9% in premarket trading, while Stratasys ( SSYS ) was 3.6% higher.

Price: 4.3400, Change: -0.17, Percent Change: -3.77